Gsk (GSK) Depreciation & Amortization (CF) (2009 - 2015)

Gsk's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $1.4 billion for Q4 2015.

• In Q4 2015, Depreciation & Amortization (CF) rose 9.53% year-over-year to $1.4 billion; the TTM figure through Sep 2016 stood at $1.4 billion (up 9.53% YoY), while the FY2018 annual figure was $1.3 billion, changed 0.11% from the prior year.
• Depreciation & Amortization (CF) for Q4 2015 stood at $1.4 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.4 billion in Q4 2011, with the low at $1.2 billion in Q4 2013.
• The 5-year median for Depreciation & Amortization (CF) is $1.4 billion (2015), against an average of $1.3 billion.
• The sharpest annual moves came in 2011 and 2015: Depreciation & Amortization (CF) dropped 22.49% in 2011, then grew 9.53% in 2015.
• Gsk's Depreciation & Amortization (CF) stood at $1.4 billion in 2011, then dropped by 0.33% to $1.4 billion in 2012, then retreated by 15.27% to $1.2 billion in 2013, then gained by 4.28% to $1.2 billion in 2014, then increased by 9.53% to $1.4 billion in 2015.
• Business Quant data shows GSK's Depreciation & Amortization (CF) at $1.4 billion in Q4 2015, $1.2 billion in Q4 2014, and $1.2 billion in Q4 2013.